Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course

Diffuse large B-cell lymphoma (DLBCL) is the most frequent, complex and heterogeneous lymphoma of adulthood. Heterogeneity is expressed at clinical, genetic, and molecular levels. It is known that BCL-6 expression is a favorable prognostic factor in DLBCL. However, the underlying mechanisms of BCL-6 expression in DLBCL relapse are not yet elucidated. Here, we present so far undescribed clinical phenomenon of switching BCL-6⁺ protein expression into BCL-6⁻ expression in 19 of 41 relapsed DLBCL patients. The switch in relapsed DLBCL was associated with more aggressive clinical course of the disease. Bone marrow infiltration and high IPI risk were more often present in BCL-6⁻ patients. Significantly increased biochemical parameters, such as LDH, beta-2 macroglobulin, CRP, and ferritin have been found, as well as significantly decreased serum Fe, TIBC, and hemoglobin. A Ki-67 proliferation marker was considerably high in relapsed DLBCL, but without significant differences between BCL-6⁺ and BCL-6⁻ groups of patients. Thus, switching of the positive into negative BCL-6 expression during DLBCL relapse could be used as a prognostic factor and a valuable criterion for treatment decision.     

瑞舒伐他汀隔日与每日治疗对血脂异常患者血脂及炎症标志物的影响

目的研究瑞舒伐他汀隔日给药10mg与每日给药10mg对血脂异常患者的血脂和炎症标志物的治疗差异。方法将37例患者随机分为2组,分别接受瑞舒伐他汀隔日给药10mg(N=19)和每日给药10mg(N=18)治疗6周后,比较用药前后血清中的低密度脂蛋白胆固醇(LDL-C),和血浆中C-反应蛋白(CRP)、白细胞介素-6(IL-6)的浓度变化。结果服药6周后,隔日治疗组和每日治疗组患者血清LDL-C、CRP、IL-6浓度与治疗前相比均有明显下降,高密度脂蛋白胆固醇和甘油三酯均有明显改善,但治疗效果两组间相比无统计学差异(P>0.05)。结论 10mg瑞舒伐他汀隔日治疗和每日治疗能同样有效改善中国患者的血脂和炎性标记物水平。     

整合素αvβ6:一种新的诊断口腔鳞状细胞癌侵袭潜能指标

目的:观察整合素αvβ6在人口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)中的表达,探讨其表达与临床病理参数之间的关系.方法:采用免疫组化及Image Pro Plus 6.0软件分析OSCC内αvβ6的IA值,并进行统计学处理.结果:癌组织的胞膜及胞浆中广泛出现αvβ6着色,而在正常口腔黏膜和良性上皮肿瘤中αvβ6不表达或弱表达.高、中及低分化癌中αvβ6的IA值分别为74.0128、132.892、259.432.αvβ6的表达在分化程度和肿瘤细胞活性方面存在统计学上的差异(P＜0.05).结论:αvβ6的表达强弱与细胞的侵袭或者异质间粘附密切相关,其表达的强弱可以作为口腔鳞状细胞癌侵袭与转移的一种指示剂.     

The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model

Abstract

Objective: Cytokine based immunotherapy has long been an exciting field for many investigators aiming to provide an effective alternative treatment modality for glioma management. Among these cytokines, interleukin-12 (IL-12) plays a crucial role in mediating inflammatory and antitumoral activity on the host defence. We have investigated the therapeutic role of systemic and local delivery of IL-12 in C6 rat glioma model and compared these two modalities.

Methods: The donor C6 glioma cells were injected stereotactically to 32 Wistar rats and right frontal tumor formation was established in all subjects. The rats were evenly divided into four groups as intratumoral (i.t.) control group (Group IA), intraperitoneal (i.p.) control group (Group IB), i.t. treatment group (Group II) and i.p. treatment group (Group III). Magnetic resonance imaging were performed to 12 rats (three from each group) on the seventh post-inoculation day. Recombinant mouse IL-12 (rmIL-12) was administered via i.t. (0.1 μg 5 μl/day/rat) and i.p. (0.1 μg 20 μl/day/rat) routes to treatment groups between days 9 and 11 following tumor inoculation, for 3 consecutive days. The rats which were unresponsive to the external stimuli, unable to feed themselves or having severe neurological impairment were decapitated and the specimens were histopathologically examined.

Results: The subjects of Group III (i.p.) showed a statistically significant prolongation in survival time (mean=39 days) when compared to the control group (mean=31.7 days) (p=0.035) and Group II (i.t.) (mean=24.5 days) (p=0.005). Histopathologic examination of Group III revealed markedly increased intratumoral and peritumoral lymphocyte infiltration compared with the other groups.

Conclusion: This study demonstrated that systemic administration of IL-12 in C6 glioma model in rats prolongs the survival, probably by stimulating the cellular immunity leading to lymphocytic infiltration.     

子宫内膜异位症患者血清及腹腔液6-异前列腺素F1α的表达及意义

目的探讨子宫内膜异位症（内异症）患者血清及腹腔液中6-异前列腺素F1α（6-k-PGF1α）的表达及其在内异症发病中的作用。方法选择2010年6月至2012年1月在我院妇科手术治疗并经病理证实为内异症的42例患者并进行分期,其中早期（Ⅰ期、Ⅱ期）20例,晚期（Ⅲ期、Ⅳ期）22例;并选择同期无月经改变、病理证实为正常子宫内膜的子宫肌瘤患者20例。所有患者均在术前采集上肢静脉血,术中采集腹腔液。采用酶联免疫吸附（ELISA）方法测定血液和腹腔液中6-k-PGF1α的水平,并对内异症患者血清和腹腔液中6-k-PGF1α的表达进行Pearson相关性分析。结果①内异症早期组、晚期组血清、腹腔液中6-k-PGF1α水平均比对照组明显增高（均P〈0.05）;②内异症晚期组组血清、腹腔液中6-k-PGF1α水平均比内异症早期组明显增高（P〈0.05）;③内异症组血清与腹腔液6-k-PGF1α水平之间呈明显正相关（r=0.580,P=0.008）。结论内异症患者血清及腹腔液中6-k-PGF1α水平明显增高,后者可作为评判内异症严重程度的参考指标。